新薬デリバリーシステム（NDDS）の世界市場：2023-2030年

世界のNDDS市場は予測期間（2024-2031年）にCAGR 21.6％で成長すると予測されます。市場の成長は、標的治療に対する需要の高まりに起因しています。糖尿病に関連するリスクの増加に基づき、心血管問題を管理するためのより特異的で焦点を絞った医薬品に対する需要が高まっています。NDDSは、薬剤を患部に直接投与することで、治療効果を高めながら全身的な副作用を減らすという可能性を提供します。国立医学研究所によると、2021年10月、幅広い地域から40歳から74歳の成人3,908人を対象とした研究が行われました。彼らの心代謝プロファイルが評価され、その頸動脈が両側から検査されました。頸動脈プラークおよび糖尿病（DM）の有病率は、それぞれ34.4％および10.7％でした。他の従来の危険因子で修正した場合、DM患者は、非DM対照者と比較して、頸動脈プラーク、総プラーク数、最大径狭窄（30％）およびプラークの有病率が高くなります。（多変量調整ORは、頸動脈プラークで1.60、総プラーク数で2.06、最大径狭窄で1.3、プラークスコアで2.03）

セグメント別の展望

経口ドラッグデリバリーシステムが世界のNDDS市場で大きなシェアを占めると予想されます。

投与経路のうち、デジタル経口ドラッグデリバリーシステムサブセグメントが世界のNDDS市場でかなりのシェアを占めると予想されます。このセグメントの成長は、効果的な経口療法に対する需要に起因しています。がん、心血管、感染症、糖尿病など、さまざまな疾患カテゴリーにおいて、より効果的な経口薬が望まれていることが大きな促進要因となっています。EUDRATEC SoluFlowの強化された経口医薬品の開発を可能にする能力は、市場の需要と合致しています。例えば、Evonik は2022年3月、経口低分子の溶解性を向上させる新しいEUDRATEC技術を発表しました。エマルジョンベースのプロセス技術であるEUDRATEC SoluFlowは、溶解度の制約を克服し、がん、心血管、感染症、糖尿病など様々な疾患に対する革新的な経口治療薬の開発を可能にします。

地域別展望

世界のNDDS市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。なかでも北米は、人口増加と政府支援によるヘルスケア産業の恩恵を受けているため、世界市場で突出したシェアを占めると予想されます。

北米地域は世界の新薬デリバリーシステム（NDDS）市場において著しいCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されています。この地域の成長は、地域全体で効果的な治療に対する需要が増加していることに起因しています。長期的な呼吸器疾患の罹患率の上昇により、より効果的な治療法に対する需要が高まっています。カスタマイズされたドラッグデリバリーシステムは、治療結果を大幅に改善し、疾患の重症度を軽減する可能性があるため、ニーズを満たすことができます。MDPIによると、2023年8月、喘息や慢性閉塞性肺疾患（COPD）を含む慢性炎症性呼吸器疾患は世界的に大きな影響を及ぼし、数百万人が罹患し、肺疾患の罹患率と死亡率の上昇に寄与しています。世界では3億人以上が喘息に罹患し、2020年にはCOPDが死因の第3位となることから、より効果的な治療法の開発が急務となっています。近年、ナノ粒子を用いたアプローチ、吸入コルチコステロイド、新規生物学的製剤、遺伝子治療、個別化医療などの標的ドラッグデリバリーシステムが、薬効を向上させ、副作用を軽減する上で有望視されています。ナノ粒子を利用して薬剤をカプセル化し、肺の特定の細胞に直接送達することで、研究者らは薬剤の送達効率を高めると同時に、オフターゲット効果を最小限に抑え、持続的な放出と治療効果の延長の可能性を提供することを目指しています。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主な調査結果
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Abbott Laboratories
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Amgen Inc. and Amgen USA Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• AstraZeneca
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 新薬デリバリーシステム（NDDS）の世界市場：投与経路別
  • 経口ドラッグデリバリーシステム（DDS）
  • 注射ドラッグデリバリーシステム（DDS）
  • 肺ドラッグデリバリーシステム（DDS）
  • 経皮ドラッグデリバリーシステム（DDS）
  • その他（経鼻ドラッグデリバリーシステム（DDS）、埋め込み型ドラッグデリバリーシステム（DDS））
• 新薬デリバリーシステム（NDDS）の世界市場：NDDSモード別
  • 標的ドラッグデリバリーシステム
  • ドラッグデリバリー制御システム
  • 変調ドラッグデリバリーシステム
  • その他（生物製剤ベースのドラッグデリバリーシステム、ナノ投与経路ベースのドラッグデリバリーシステム）

第5章 地域分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域

第6章 企業プロファイル

• Bayer AG
• Boston Scientific Corp.
• Bristol Myers Squibb（BMS）
• Celgene Corp.
• At F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Merck KGaA,
• Novartis International AG
• Pfizer Inc.
• Assertio Holdings, Inc.
• Gilead Sciences, Inc
• Medtronic Pvt. Ltd.
• Becton, Dickinson, and Co.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Cipla Ltd.

LIST OF TABLES

• 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2023-2031 ($ MILLION)
• 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
• 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 13. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 14. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
• 15. NORTH AMERICAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
• 16. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 17. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
• 18. EUROPEAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
• 19. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
• 20. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
• 21. ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)
• 22. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
• 23. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION , 2023-2031 ($ MILLION)
• 24. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET RESEARCH AND ANALYSIS BY MODE OF NDDS, 2023-2031 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY ROUTE OF ADMINISTRATION, 2023 VS 2031(%)
• 2. GLOBAL ORAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 3. GLOBAL INJECTABLE DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 5. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 6. GLOBAL OTHER DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 7. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY MODE OF NDDS, 2023 VS 2031(%)
• 8. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY TARGETED MARKET SHARE BY REGION, 2023 VS 2031(%)
• 9. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY CONTROLLED MARKET SHARE BY REGION, 2023 VS 2031(%)
• 10. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY MODULATED MARKET SHARE BY REGION, 2023 VS 2031(%)
• 11. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) BY OTHERS MARKET SHARE BY REGION, 2023 VS 2031(%)
• 12. GLOBAL NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SHARE BY REGION, 2023 VS 2031(%)
• 13. US NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 14. CANADA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 15. UK NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 16. FRANCE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 17. GERMANY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 18. ITALY NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 19. SPAIN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 20. REST OF EUROPE NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 21. INDIA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 22. CHINA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 23. JAPAN NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 24. SOUTH KOREA NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 25. REST OF ASIA-PACIFIC NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)
• 26. REST OF THE WORLD NEW DRUG DELIVERY SYSTEMS (NDDS) MARKET SIZE, 2023-2031 ($ MILLION)

Global New Drug Delivery Systems (NDDS) Market Size, Share & Trends Analysis Report by Route of Administration (Oral Drug Delivery Systems (DDS), Injectable Drug Delivery Systems (DDS), Pulmonary Drug Delivery Systems (DDS), Transdermal Drug Delivery Systems (DDS), and Others ), and by Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Others) Forecast Period (2024-2031)

The global NDDS market is anticipated to grow at a CAGR of 21.6% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for targeted therapies. Based the increased risks associated with diabetes, there is rising demand for more specific and focused medicines for managing cardiovascular problems. NDDS provides a possibilities by allowing drugs to be delivered directly to afflicted locations, decreasing systemic side effects while increasing the effectiveness of therapy. According to the National Institute of Medicine, in October 2021, the study included 3,908 adults aged 40 to 74 years from a wide range of regions. Their cardiometabolic profiles were evaluated, and its carotid arteries were examined bilaterally. The prevalence rates of carotid plaque and diabetic mellitus (DM) were 34.4% and 10.7%, respectively. when modifying for other conventional risk factors, DM patients had higher prevalence rates of carotid plaque, total plaque number, maximum diameter stenosis (30%), and plaque (multivariable-adjusted OR 1.60 for carotid plaque, 2.06 for total plaque number, 1.3 for maximum diameter stenosis, and 2.03 for plaque score) than non-DM controls.

Segmental Outlook

The global NDDS market is segmented on the route of administration, and mode of NDDS. Based on the route of administration, the market is sub-segmented oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others. Furthermore, on the basis of mode of NDDS, the market is sub-segmented into targeted drug delivery systems, controlled drug delivery systems, modulated drug delivery systems, and others. The Injectable drug delivery systems subcategory is expected to capture a significant portion of the market share within the route of administration segment. The growth can be attributed to the growing number of vaccination's drives across the globe propelling the demand for instruments.

The Oral Drug Delivery Systems Sub-Segment is Anticipated to Hold a Considerable Share of the global NDDS Market

Among the route of administration, the digital oral drug delivery systems sub-segment is expected to hold a considerable share of the global NDDS market. The segmental growth is attributed to the demand for effective oral therapies. The desire for more effective oral medicines in a variety of disease categories, including cancer, cardiovascular, infectious, and diabetes, is a major driving force. EUDRATEC SoluFlow's ability to enable the development of enhanced oral pharmaceuticals aligns with a market demand. For instance, in March 2022, Evonik launched new EUDRATEC technology to improve solubility of oral small molecules. The EUDRATEC SoluFlow, an emulsion-based process technique, overcomes solubility constraints, allowing the development of innovative oral therapies for a variety of diseases such as cancer, cardiovascular, infectious, and diabetes.

Regional Outlook

The global NDDS market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the healthcare industry benefits from a growing population and government support.

The North America Region is Expected to Grow at a Significant CAGR in the global New Drug Delivery Systems (NDDS) Market

Among all regions, North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for effective treatments across the region. The rising incidence of long-term respiratory diseases has resulted in a high demand for more effective therapies. Customized drug delivery systems have the potential to significantly improve treatment outcomes and reduce disease severity, thus satisfying the need. According to MDPI, in August 2023, the chronic inflammatory respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), have a significant global impact, affecting millions of people and contributing to the rise in lung disease morbidity and mortality. With over 300 million individuals globally affected by asthma and COPD becoming the third leading cause of death in 2020, there is a pressing need for more effective treatments. In recent years, targeted drug delivery systems, such as nanoparticle-based approaches, inhaled corticosteroids, novel biologicals, gene therapy, and personalized medicine, have shown promise in improving drug efficacy and reducing side effects. By utilizing nanoparticles to encapsulate and deliver drugs directly to specific cells in the lungs, researchers aim to enhance drug delivery efficiency while minimizing off-target effects, offering potential for sustained release and prolonged therapeutic effects.

Market Players Outlook

The major companies serving NDDS market includes Bayer AG, Boston Scientific Corp., Johnson & Johnson Services, Inc., and Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2022, EVERSANA, and Accord BioPharma, partnered to launched CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

The Report Covers:

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global NDDS market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abbott Laboratories
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Amgen Inc. and Amgen USA Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. AstraZeneca
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global New Drug Delivery Systems (NDDS) Market by Route of Administration
  • 4.1.1. Oral Drug Delivery Systems (DDS)
  • 4.1.2. Injectable Drug Delivery Systems (DDS)
  • 4.1.3. Pulmonary Drug Delivery Systems (DDS)
  • 4.1.4. Transdermal Drug Delivery Systems (DDS)
  • 4.1.5. Others (Nasal Drug Delivery Systems (DDS), and Implantable Drug Delivery Systems (DDS))
• 4.2. Global New Drug Delivery Systems (NDDS) Market by Mode of NDDS
  • 4.2.1. Targeted Drug Delivery Systems
  • 4.2.2. Controlled Drug Delivery Systems
  • 4.2.3. Modulated Drug Delivery Systems
  • 4.2.4. Others (Biologics-Based Drug Delivery Systems, and NanoRoute of Administration -Based Drug Delivery Systems)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Bayer AG
• 6.2. Boston Scientific Corp.
• 6.3. Bristol Myers Squibb (BMS)
• 6.4. Celgene Corp.
• 6.5. At F. Hoffmann-La Roche Ltd.
• 6.6. GlaxoSmithKline PLC
• 6.7. Johnson & Johnson Services, Inc.
• 6.8. Merck KGaA,
• 6.9. Novartis International AG
• 6.10. Pfizer Inc.
• 6.11. Assertio Holdings, Inc.
• 6.12. Gilead Sciences, Inc
• 6.13. Medtronic Pvt. Ltd.
• 6.14. Becton, Dickinson, and Co.
• 6.15. Teva Pharmaceutical Industries Ltd.
• 6.16. Mylan N.V.
• 6.17. Cipla Ltd.